18546750. SELECTIVE NEUTRAL PH INHIBITOR OF CATHEPSIN B simplified abstract (The Regents of the University of California)

SELECTIVE NEUTRAL PH INHIBITOR OF CATHEPSIN B

Organization Name

The Regents of the University of California

Inventor(s)

Anthony O'donoghue of La Jolla CA (US)

Vivian Hook of La Jolla CA (US)

Michael Yoon of La Jolla CA (US)

Dennis Wolan of La Jolla CA (US)

SELECTIVE NEUTRAL PH INHIBITOR OF CATHEPSIN B - A simplified explanation of the abstract

This abstract first appeared for US patent application 18546750 titled 'SELECTIVE NEUTRAL PH INHIBITOR OF CATHEPSIN B

The patent application pertains to pharmaceutical compositions containing a peptidic inhibitor of cathepsin B, such as Z-Arg-Lys-AOMK (Z-R-K-AOMK), for inhibiting neutral pH cathepsin B activity and treating or preventing diseases.

• Peptidic inhibitor Z-R-K-AOMK effectively inhibits cathepsin B activity.
• Methods involve administering Z-R-K-AOMK to subjects in need to inhibit cathepsin B.
• Production of pH-selective peptide-AMC substrates and novel peptidic-AOMK inhibitors of cathepsin B is detailed.

Potential Applications

The technology can be applied in pharmaceuticals for treating various diseases involving cathepsin B activity, such as cancer and neurodegenerative disorders.

Problems Solved

This innovation addresses the need for effective inhibitors of cathepsin B to regulate its activity in disease conditions and improve treatment outcomes.

Benefits

The use of Z-R-K-AOMK as a peptidic inhibitor offers a targeted approach to inhibit cathepsin B, potentially leading to better disease management and therapeutic interventions.

Commercial Applications

The technology has significant commercial potential in the pharmaceutical industry for developing novel treatments targeting cathepsin B-related diseases, potentially opening up new market opportunities.

Prior Art

Prior research has explored various inhibitors of cathepsin B, but the specific peptidic inhibitor Z-R-K-AOMK presents a unique approach to targeting this enzyme.

Frequently Updated Research

Ongoing research focuses on optimizing the efficacy and specificity of peptidic inhibitors like Z-R-K-AOMK for cathepsin B inhibition in different disease contexts.

Questions about Peptidic Inhibitor of Cathepsin B

What are the potential applications of Z-R-K-AOMK beyond inhibiting cathepsin B?

Z-R-K-AOMK could potentially be explored for its effects on other proteases or enzyme targets in various disease pathways.

How does Z-R-K-AOMK compare to other inhibitors of cathepsin B in terms of efficacy and specificity?

Research comparing Z-R-K-AOMK with existing inhibitors could provide insights into its advantages and limitations in inhibiting cathepsin B.

Original Abstract Submitted

Pharmaceutical compositions comprising a peptidic inhibitor of cathepsin B, such as Z-Arg-Lys-AOMK (Z-R-K-AOMK). Methods for inhibiting neutral pH cathepsin B activity, comprising administering to a subject in need an effective amount of a peptidic inhibitor of cathepsin B. Methods for treatment or prevention of a disease comprising administering to a subject in need an effective amount of a peptidic inhibitor of cathepsin B. Methods of producing pH-selective peptide-AMC substrates and novel peptidic-AOMK inhibitors of cathepsin B.